[1] Gao S, Ma JJ, Lu C. Prognostic significance of VEGFC immunohistochemical expression in breast cancer: a metaanalysis[J]. Tumor Biology, 2014, 35(2): 1523-1529. [2] Widodo I, Ferronika P, Harijadi A, et al. Clinicopathological significance of lymphangiogenesis and tumor lymphovascular invasion in indonesian breast cancers[J]. Asian Pac J Cancer Prev, 2013, 14(2): 997-1001. [3] 任彦武, 高峰, 宋枫, 等. 结直肠癌组织中VEGFC和Podoplianin表达临床意义分析[J]. 中华肿瘤防治杂志, 2013, 20(20): 1592-1595. [4] Wang TB, Chen ZG, Wei XQ, et al. Serum vascular endothelial growth factorC and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer[J]. ANZ J Surg, 2011, 81(10): 694-699. [5] Tacconi C, Correale C, Gandelli A, et al. Vascular endothelial growth factor C disrupts the endothellal lymphatic barrier to promote colorectal cancer invasion[J]. Gastroenterology, 2015, In Press. [6] Lin PC, Lin YJ, Lee CT, et al. Cyclooxygenase2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients[J]. Oncol Lett, 2013, 6(3): 733-739. [7] Liu H, Xiao J, Yang Y, et al. COX2 expression is correlated with VEGFC, lymphangiogenesis and lymph node metastasis in human cervical cancer[J]. Microvasc Res, 2011, 82(2): 131-140. [8] 张涛, 李焱, 高辉, 等. 结肠癌中COX2对VEGFC表达的影响[J]. 现代肿瘤医学, 2009, 17(12): 2401-2403. [9] Cao R, Ji H, Feng N, et al. Collaborative interplay beteeen FGF2 and VEGFC promotes lymphangiogenesis and metastasis[J]. Pro Natl Acad Sci USA, 2012, 109(39): 15894-15899. [10] Chang LK, GarciaCardena G, Famebo F, et al. Dosedependent response of FGF2 for lymphangiogenesis[J]. Proc Natl Acad Sci USA, 2004, 101(32): 11658-11663. [11] Sundlisaeter E, Rosland GV, Hertel JK, et al. Increased lymphatic vascular density is seen before colorectal cancers reach stage Ⅱ and growth factor FGF2 is downregulated in tumor tissue compared with normal mucosa[J]. APMIS, 2009, 117(3): 212-221. [12] 张伟, 于占江, 师岩, 等. 趋化因子受体CCR7的表达与卵巢癌淋巴管入侵及淋巴结转移的关系[J]. 解剖科学进展, 2012, 18(5): 456-459. [13] 武欣, 李坤, 张凡, 等. 大肠癌中CCR7、Lselectin、CD44v6和 MMP9表达及其与淋巴转移的关系[J]. 临床与实验病理学杂志, 2013, 29(1): 32-35. [14] Pryczynicz A, Gryko M, Niewiarowska K, et al. Immunohistochemical expression of MMP7 protein and its serum level in colorectal cancer[J]. Folia Histochem Cytobiol, 2013, 51(3): 206-212. [15] Kostova E, SlaninkaMiceska M, Labacevski N, et al. Expression of matrix metalloproteinasws 2, 7 and 9 in patuents with colorectal cancer [J]. Vojnosanit Pregl, 2014, 71(1): 52-59. [16] 李志娟, 蒋卫国, 王劲欧, 等. CD151和MMP7在结直肠癌中的表达及其临床意义[J]. 中国肿瘤临床, 2012, 39(7): 392-395. [17] 吴桂丽, 胡月明, 刘爱东, 等. 结直肠腺癌中MMP7的表达与淋巴管生成的关系[J]. 现代肿瘤医学, 2012, 20(3): 553-557. [18] Petrelli F, Coinu A, Ghilardi M, et al. Efficacy of oxaliplatinbased chemotherapy+bevacizumab as firstline treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trialsy[J]. Am J Clin Oncol, 2015, 38(2): 227-233. [19] Harada K, Hatanaka K, Kinoshita K, et al. Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as firstline treatment—a case report[J]. Gan To Kagaku Ryoho, 2014, 41(7): 897-900. |